



Vlad Coric, M.D. Chairman and Chief Executive Officer

In his over seven years as CEO of Biohaven, Dr. Coric led the company in the pursuit of its bold vision from an entrepreneurial start-up into a modern, publicly traded company listed on the New York Stock Exchange with the mission of advancing novel medications to underserved patients. His leadership translated into dramatic growth for the company, from its initial pre-money valuation of about \$6M to the sale of the company for \$13B in total considerations. Dr. Coric successfully led the company through its first FDA approval and the launch of Nurtec® ODT (rimegepant; CGRP receptor antagonist) for the acute treatment of migraine. A little more than one year later, Biohaven transformed the migraine treatment paradigm with the FDA approval of an expanded indication for Nurtec ODT for the preventive treatment of episodic migraine – becoming the first all-in-one migraine medication for the acute and preventive treatment of migraine. Biohaven also received approval in Europe and other major markets – advancing its “treat and prevent” migraine therapy to the approximately one billion patients suffering from migraine across the world. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. Capitalizing on the extraordinary patient and shareholder value that Biohaven has built with Nurtec ODT and its CGRP franchise, Dr. Coric spearheaded the acquisition of Biohaven by Pfizer in May 2022 for approximately \$13 billion in total consideration.

Dr. Coric has positioned Biohaven on its new course continuing its growth trajectory, harnessing its proven drug development expertise, extensive portfolio of clinical-stage assets and robust discovery research capabilities. The pillars of the company’s success – Commitment to Patients, Winning with Science and Creating Shareholder Value – continue to be the foundation of Biohaven’s ongoing growth.

Under Dr. Coric’s stewardship, Biohaven has focused on discovering, developing and commercializing life-changing therapies that address unmet medical needs. The company’s focus on scientific innovation is evidenced in its broad therapeutic portfolio comprised of early- and late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, with little or no treatment options. These include epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA). In February 2022, Dr. Coric led Biohaven’s acquisition of a novel Kv7 channel targeting platform – adding the latest advances in ion-channel modulation to Biohaven’s neuroscience portfolio.

A proponent of innovation that extends beyond the R&D cycle to all aspects of pharmaceutical operations, Dr. Coric has been instrumental in establishing Biohaven’s agile, digital-centric operating and commercial model. Today, Biohaven is an industry leader in the use of digital tools and technologies to increase patient engagement and enhance the success of its novel treatments. Dr. Coric has also led the expansion of Biohaven to international markets, including the formation of subsidiaries in Ireland and Asia-Pacific.

Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor).

Since July 2001, Dr. Coric has also continued to serve as an Associate Clinical Professor of Psychiatry at Yale School of Medicine. He previously served as the inpatient chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as president of the Connecticut Psychiatric Society. Dr. Coric has authored more than 65 peer-reviewed publications. Dr. Coric completed his internship at Yale-New Haven Hospital and residency training at the Yale Psychiatry Residency Training Program, where he also served as the program-wide chief resident for the Yale Department of Psychiatry, and chief resident on the PTSD service at the West-Haven Connecticut Veterans Administration Hospital.

Dr. Coric earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. He was named one of the Top 25 Healthcare Technology Leaders of Connecticut for 2022 by The Healthcare Technology Report. He was the recipient of the Ernst & Young Entrepreneur of the Year 2018 Award in the New York region.